| Total | 3.305, 92 | 185, 5 | |
| Women | 2.891, 90 | 176, 95 | 0.02 |
| Myositis | 113, 3 | 15, 8 | 0.001 |
| Hemolytic anemia | 271, 8 | 24. 14 | 0.01 |
| Lupus nephritis | 952, 29 | 79, 44 | <0.0001 |
| Serositis | 49, 1 | 9, 5 | <0.001 |
| Admissions related to LES activity | 1.741, 54 | 120, 67 | 0.0001 |
| Median (IQR) | Median (IQR) | |
| Age at SLE diagnosis (years) | 35.5 (24.3–44.5) | 30.5 (22.6–36.9) | 0.001 |
| Age at the study inclusion | 32.8 (22–42) | 28.6 (21–36) | <0.001 |
| SLA disease duration (years) |
| 1st symptom to diagnosis | 12.5 (5.7–17.5) | 7.9 (2.5–10.7) | <0.0001 |
| Activity (SLEDAI) | 2.5 (0–4) | 3.8 (0–4) | 0.01 |
| Severity (KATZ) | 2.6 (1–3) | 2.9 (2–4) | 0.01 |
| Damage (SLICC) | 1.1 (0–2) | 0.9 (0–1) | 0.6 |
| Comorbidity (Charlson) | 2.3 (1–3) | 1.7 (1–2) | 0.2 |